Novanta is trading 4.7% down now at $160.80 as technology stocks lead a broader market pullback.
- No clearly identified company-specific announcement explains the August 18, 2026 decline.
- Recent coverage highlights strong second-quarter results, upgraded 2026 guidance, and the Riverpoint Medical acquisition.
- Elevated bond yields, higher oil prices, and fading U.S.-Iran peace hopes weigh on markets; the Nasdaq is down 1.37% and the S&P 500 is down 0.61%.